A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D

The policy announced by Commissioner Martin A. Makary, MD, will not preclude employees of regulated companies from presenting their views to committees, and rare exceptions will be allowed.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Calculating the amount of drug needed for compounding requires different considerations for respective drug types and forms.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Development of the state-of-the-art facility was made possible by a £2 million (US$2.6 million) round of funding, and a successful inspection by MHRA was completed in March 2025.

The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.